Infectious bursal disease (IBD) is an economically important disease in poultry worldwide ([@R18]). The disease in broilers is characterised by mortality, immunosuppression due to destruction of B cells and macrophages and decreased economic performance ([@R16], [@R18]). In broilers, current strategies for prevention and control of IBD include passive immunological protection, hygiene and vaccination on the broiler farm with live attenuated vaccines ([@R11], [@R10]). Early passive protection of the broiler against infection can be conferred through maternally derived antibody (MDA)([@R15], [@R13]). For this, it is common to use inactivated IBD vaccines in breeders that have been primed earlier with live IBD vaccine in the rearing period to generate levels of MDA in progeny chicks. This elevated MDA will confer early protection against IBD infection in these progeny ([@R8], [@R18]). Vaxxitek HVT+IBD (Merial Animal Health Ltd) is a novel vector vaccine in which the IBD virus gene (VP2 gene) coding for VP2 protein of IBD virus has been inserted into a turkey herpes virus ([@R2]). This vaccine when inoculated into chicken causes the expression of the IBD VP2 protein with subsequent antigen/antibody response by the birds ([@R3]). Antibodies to the IBD VP-2 protein are recognised as being the most important of the neutralising antibodies that confer protection against infection ([@R9]). Protective levels of MDA to IBD have been demonstrated in progeny of Vaxxitek HVT+IBD vaccinated breeders ([@R12]). Knowledge of the antibody development during the laying period is important as it has direct consequences for the age that the progeny can be vaccinated using conventional live IBD vaccines ([@R1]). The purpose of this study was to compare (under British field conditions) the humoral IBD immune response in breeders vaccinated with a single dose of Vaxxitek HVT+IBD in ovo at 18 days of incubation with breeders vaccinated with Vaxxitek HVT+IBD in ovo at 18 days incubation plus an inactivated IBD vaccine at transfer to the laying farm (18 weeks). Humoral antibody response in the breeders and the transfer to the progeny was measured by two commercially available ELISAs and virus neutralisation tests at various time points through the laying cycle.

Methods {#s1}
=======

Breeders {#s1a}
--------

Cobb 500 breeders were vaccinated in ovo at 18 days incubation in the parent hatchery with Vaxxitek HVT+IBD and Cryomarex Rispens (CVI 988) (Merial Animal Health Ltd) and placed on the same rearing site. All birds received the same vaccination programme in rear, no other live IBD priming vaccine was administered in rear or in lay. Prior to transfer at 18 weeks, multivalent oil emulsion vaccine Nobilis RT+IBmulti+G+ND (MSD Animal Health Ltd) containing an inactivated IBD antigen (D78 strain) was administered to 50 per cent of the birds (inactivated IBD group). A multivalent oil emulsion vaccine Gallimune 407 ND+IB+EDS+ART (Merial Animal Health Ltd) without an IBD antigen was administered to the remaining 50 per cent of the birds (Vector IBD group). Both treatment flocks were housed on the same laying farm with two houses allocated to each treatment. Clotted blood samples were collected from the breeders when they were 15 weeks old, prior to the administration of the inactivated vaccine. Further clotted blood samples were collected from both groups when the birds were aged 22, 27, 32, 36, 41, 45, 56 and 60 weeks old on the laying farm. Serum was harvested from the clotted blood samples and assayed for IBD antibodies levels using two commercially available ELISA tests and a virus neutralization test.

Progeny {#s1b}
-------

At three time points in the laying cycle, hatching eggs from the two treatment groups were set separately for incubation. On hatching, day-old chicks were blood sampled to assess levels of maternally derived IBD antibodies using two commercially available ELISA tests and a virus neutralisation assay.

### ELISAs {#s1b1}

Two commercially available ELISAs (BioChek CV, Gouda, The Netherlands), IDEXX FlockChek standard (IDEXX Corporation, Westbrook, Maine, USA), for the detection of antibodies directed against IBD were assayed as indicated by the manufacturer\'s instructions.

### Virus neutralisation assay {#s1b2}

The assay was based on the method described by [@R17]) and [@R14]) with some modifications. The end point of the virus neutralisation titre (VNT) on a serum sample was determined to be the reciprocal of the highest dilution, expressed in log~2~, which completely neutralised 100 TCID~50~ of IBDV D78 strain.

### Statistics {#s1b3}

Analysis of variance (ANOVA) and Tukey test were used to compare the difference in the mean IBD titres of the vector and inactivated IBD groups at the various ages through the trial. ANOVA and Student *t* test were used to compare the difference in mean titres between vector and inactivated IBD groups at each sampling time for each of the three serology test assays.

Results {#s2}
=======

The mean IBD antibody levels in the breeder flocks at the nine time points in the rearing and laying cycle as measured by VNT and ELISA are tabulated in [Tables 1](#VETRECO2013000016TB1){ref-type="table"}[](#VETRECO2013000016TB2){ref-type="table"}--[3](#VETRECO2013000016TB3){ref-type="table"}. The mean IBD antibody levels from the day-old progeny of the breeder flocks at the three time points in laying cycle as measured by virus neutralisation test and ELISA are tabulated in [Tables 4](#VETRECO2013000016TB4){ref-type="table"}[](#VETRECO2013000016TB5){ref-type="table"}--[6](#VETRECO2013000016TB6){ref-type="table"}.

###### 

Serum neutralisation infectious bursal disease (IBD) titres of breeders at different time points through lay

  Virus neutralisation titre) log~2~   Vector IBD   Inactivated IBD                                 
  ------------------------------------ ------------ ----------------- -------------- ---- --------- --------------
  15                                   10           16.1^a^           15.3 to 16.9   10   16.0^a^   15.4 to 16.6
  22                                   10           17.0^a^           16.2 to 17.8   10   17.0^a^   16.4 to 17.6
  27                                   18           16.9^a^           16.3 to 17.6   20   16.4^b^   15.9 to 16.8
  32                                   20           15.9^a^           15.3 to 16.5   20   16.1^a^   15.6 to 16.5
  36                                   20           15.6^a^           15.0 to 16.1   19   16.1^a^   15.7 to 16.5
  41                                   18           16.6^a^           16.0 to 17.2   20   16.6^a^   16.2 to 17.0
  45                                   18           16.8^a^           16.2 to 17.4   19   16.8^a^   16.3 to 17.2
  56                                   20           17.0^a^           16.4 to 17.6   19   16.6^b^   16.2 to 17.1
  60                                   19           16.7^a^           16.1 to 17.3   20   16.7^a^   16.3 to 17.1

Mean values within rows with different superscripts are significantly different (P\<0.05)

###### 

BioChek infectious bursal disease (IBD) ELISA titres of breeders at different time points through lay

  --------------------------------------------------------------------------------------
  BioChek\   Vector IBD   Inactivated IBD                                 
  ELISA                                                                   
  ---------- ------------ ----------------- -------------- ---- --------- --------------
  15         10           4368^a^           3214 to 5555   10   4384^a^   3109 to 5660

  22         10           6509^a^           5339 to 7680   10   8125^b^   6850 to 9401

  27         19           7592^a^           6743 to 8441   21   6845^a^   5965 to 7726

  32         20           5349^a^           4522 to 6177   20   5743^a^   4841 to 6645

  36         20           5497^a^           4669 to 6324   20   6828^a^   5926 to 7730

  41         20           5901^a^           5073 to 6728   20   6729^a^   5827 to 7631

  45         18           6004^a^           5132 to 6877   19   6525^a^   5600 to 7451

  56         20           7344^a^           6516 to 8172   19   7190^a^   6265 to 8116

  60         19           6917^a^           6067 to 7766   20   7438^a^   6536 to 8340
  --------------------------------------------------------------------------------------

Mean values within rows with different superscripts are significantly different (P\<0.05)

###### 

IDEXX infectious bursal disease (IBD) ELISA titres of breeders at different time points through lay

  Idexx ELISA titres   Vector IBD   Inactivated IBD                                   
  -------------------- ------------ ----------------- -------------- ---- ----------- ----------------
  15                   10           4109^a^           2875 to 5135   10   4005^a^     2756 to 5254
  22                   10           6033^a^           4903 to 7163   10   6051^a^     4802 to 7300
  27                   19           5919^a^           5099 to 6739   20   5354^a^     4471 to 6237
  32                   20           4596^a^           3797 to 5395   20   5211^a^     4328 to 6094
  36                   20           5577^a^           4778 to 6376   19   6370^a^     5464 to 7276
  41                   18           7598^a^           6756 to 8440   19   7800^a^     6894 to 8706
  45                   18           6844^a^           6002 to 7686   19   7721^a^     6815 to 8627
  56                   19           8189^a^           7369 to 9009   19   7456^a^     6550 to 8362
  60                   17           7126^a^           6259 to 7993   17   10,173^b^   9215 to 11,130

Mean values within rows with different superscripts are significantly different (P\<0.05)

###### 

Virus neutralisation test of day-old progeny at different time points through the laying cycle

  Virus neutralisation test (log~2~)   Vector IBD   Inactivated IBD                                 
  ------------------------------------ ------------ ----------------- -------------- ---- --------- --------------
  32                                   13           15.7^a^           14.9 to 16.5   19   16.0^a^   15.3 to 16.7
  46                                   18           15.7^a^           14.8 to 16.6   19   15.3^a^   14.4 to 16.2
  61                                   19           16.5^a^           16.0 to 17.1   20   16.3^a^   15.7 to 16.8

Mean values with different superscripts within rows or within columns are significantly different (P\<0.05)

IBD, infectious bursal disease

###### 

BioChek ELISA titres of day-old progeny at different time points through the laying cycle

  BioChek ELISA titres   Vector IBD   Inactivated IBD                                  
  ---------------------- ------------ ----------------- -------------- ---- ---------- --------------
  32                     13           5686^a1,2^        4684 to 6687   19   6131^a1^   5302 to 6959
  46                     18           4679^a1^          3693 to 5665   20   4279^a1^   3344 to 5215
  61                     20           6299^a2^          5061 to 7537   20   5715^a1^   4477 to 6953

Mean values with different superscript letters within rows or with different superscript numbers within columns are significantly different (P\<0.05)

IBD, infectious bursal disease

###### 

IDEXX ELISA infectious bursal disease (IBD) antibody titres at different time points during the laying cycle

  IDEXX ELISA titres   Vector IBD   Inactivated IBD                                  
  -------------------- ------------ ----------------- -------------- ---- ---------- --------------
  32                   13           4886^a1^          3789 to 5982   19   5614^a1^   4707 to 6522
  46                   18           5585^a1^          4516 to 6654   19   4604^a1^   3564 to 5645
  61                   20           7370^a2^          5892 to 8848   20   7111^a2^   5633 to 8590

Mean values with different superscript letters within rows or with different superscript numbers within columns are significantly different (P\<0.05)

The geometric mean titre (GMT) in the breeder birds during the laying period were compared with GMT titres of the progeny at day of hatch. The percentage of antibody transfer was determined and is listed in [Table 7](#VETRECO2013000016TB7){ref-type="table"}.

###### 

Virus neutralisation test and ELISA titres (BioChek and IDEXX) of breeders and their progeny

            GMT of breeders weeks 22--60   GMT of progeny hatched at 32, 46 and 60 weeks   Percentage of transfer of antibodies to the progeny                
  --------- ------------------------------ ----------------------------------------------- ----------------------------------------------------- ------- ---- ----
  VNT       16.56                          16.53                                           15.96                                                 15.84   66   62
  BioChek   12.46                          12.66                                           12.14                                                 12.07   80   66
  IDEXX     12.55                          12.67                                           12.34                                                 12.29   86   77

IBD, Infectious bursal disease

The ages at which 20 per cent or 80 per cent of the birds (progeny) would be susceptible for an intermediate IBD vaccine with a breakthrough titre of 250 were calculated using both commercial ELISAs ([@R4], [@R7], [@R1]) ([Table 8](#VETRECO2013000016TB8){ref-type="table"}).

###### 

The ages at which 20 per cent or 80 per cent of the birds (progeny) would be susceptible for a vaccine with a breakthrough titre of 250

  Age   Live vaccine      Inactivated vaccine                            
  ----- ----------------- --------------------- ---- ---- ---- ---- ---- ----
  32    Too few samples   16                    15   19   19             
  46    14                14                    18   19   14   14   18   17
  61    16                16                    19   20   12   14   19   20

Discussion {#s3}
==========

The rearing birds had similar levels of humoral IBD antibodies as measured by virus neutralisation test and ELISA in both treatment groups, the antibody levels reported were uniform and in line with expectation. High levels of humoral antibodies to IBD were achieved at point of lay and persisted throughout the laying life of both groups. Both groups were housed on the same farm so if any IBD field challenge occurred during the laying period the impact could expect to be the same for both treatment groups. Humoral antibody levels in both treatment groups (as measured by both ELISA and VN) were numerically lower at the 32- and 36-week sampling than at the earlier and later sampling points. This relatively small drop in titre was observed around the period of production of peak egg mass. [@R15]) did not observe this drop in breeder IBD antibody level in their study; however, their first sampling point was two months into the laying period and the birds used in the Naqi study were White Leghorns rather than a commercial broiler breeder strain and known to respond differently to various vaccinal antigens. At 27 and 56 weeks, there was a significant difference in the humoral IBD antibodies as measured by virus neutralisation tests between the two treatment groups. Only at a single sampling point during the laying cycle was there a significant difference in the humoral IBD antibody level in the two treatment groups as measured by both ELISA tests. In this study, the IDEXX and BioChek IBD titres were in general comparable both in the breeders ([Fig 1](#VETRECO2013000016F1){ref-type="fig"}) and in the progeny ([Fig 2](#VETRECO2013000016F2){ref-type="fig"}). In previous work with conventionally vaccinated breeders (live IBD priming and inactivated vaccine), the BioChek IBD titres were significantly higher than the IDEXX IBD titres (De [@R5]). Further studies are required to confirm whether this would be a consistent finding with the Vaxxitek HVT+IBD priming vaccination.

![IDEXX and BioChek ELISA titres for Vaxxitek and vaxxitek plus inactivated vaccinated breeders at various time points through the laying period](vetreco2013000016f01){#VETRECO2013000016F1}

![Day-old IDEXX and BioChek ELISA titres for the progeny of Vaxxitek and vaxxitek plus inactivated vaccinated breeders at various time points through the laying period](vetreco2013000016f02){#VETRECO2013000016F2}

The humoral IBD antibody levels in the day-old progeny of these flocks did not show any significant difference between the treatment groups as measured by either SN ([Fig 3](#VETRECO2013000016F3){ref-type="fig"}) or ELISA ([Fig 2](#VETRECO2013000016F2){ref-type="fig"}) tests. Although mean levels of the IBD MDA were significantly different across the different sampling points as measured by both ELISAs, when these titres were used to predicted vaccination dates using the Deventer formula the predicted dates for vaccination were not significantly different between the progeny of both treatment groups. This is an important observation for field veterinarians since day-old MDA as measured by ELISA is used in the field to help determine the optimal timing of live IBD vaccination in the broiler chicks ([@R14], [@R1]). The level of transfer of antibodies from breeder to progeny ([Table 7](#VETRECO2013000016TB7){ref-type="table"}) was comparable to earlier results with these tests ([@R5]).

![Day-old virus neutralization titres for the progeny of Vaxxitek and vaxxitek plus inactivated vaccinated breeders at various time points through the laying period](vetreco2013000016f03){#VETRECO2013000016F3}

Vaxxitek HVT+IBD is a vectored vaccine using turkey herpes virus as the vector virus. PCR products of this vaccine can be recovered from broiler breeder spleen and pulpy feathers late in the laying cycle (Sue Baigent, personal communication). If the Vaxxitek HVT+IBD vaccine can be detected in tissues of the avian immune system throughout the laying period of the broiler breeder, it can be assumed that the Vaxxitek HVT+IBD will continue to stimulate the immune system and maintain circulating IBD antibody levels in the breeder. This study confirms that humoral IBD antibody levels were maintained throughout the life of both treatment groups in these breeder flocks.

There was no significant improvement in the IBD humoral antibody response in the birds vaccinated with both Vaxxitek HVT+IBD and inactivated IBD vaccine compared with those vaccinated with Vaxxitek HVT+IBD alone. It is proposed that a single application of Vaxxitek HVT+IBD vaccine will confer the same level of protection to broiler breeders as a Vaxxitek HVT+IBD and inactivated vaccination programme and that these titres remain stable throughout the laying period.
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